Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 195 entries
View as:

Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02324088 Org: User:
Start: 10/31/00 End: 01/31/15 Due: 01/31/16

Study on Androgen Receptor and Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03383679 Org: User:
Start: 03/14/18 End: 07/20/22 Due: 07/20/23

Nivolumab in Recurrent and/or Metastatic SCCHN

Phase: N/A Priority: Normal
NCT ID: NCT03226756 Org: User:
Start: 07/07/17 End: 05/31/22 Due: 05/31/23

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Phase: N/A Priority: Normal
NCT ID: NCT03848052 Org: User:
Start: 10/02/17 End: 12/31/25 Due: 12/31/26

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03386162 Org: User:
Start: 03/15/18 End: 11/18/22 Due: 11/18/23

Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00534274 Org: User:
Start: 11/30/06 End: 09/30/13 Due: 09/30/14

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05973864 Org: User:
Start: 03/11/25 End: 08/31/28 Due: 08/31/29

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT04181203 Org: User:
Start: 01/09/20 End: 12/28/33 Due: 12/28/34

Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast

Phase: N/A Priority: Normal
NCT ID: NCT03878342 Org: User:
Start: 05/10/19 End: 11/14/34 Due: 11/14/35

Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00112697 Org: User:
Start: 10/06/03 End: 03/01/12 Due: 03/01/13

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00112658 Org: User:
Start: 11/30/04 End: 06/30/10 Due: 06/30/11

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Phase: N/A Priority: Normal
NCT ID: NCT06496581 Org: User:
Start: 09/12/24 End: 08/01/39 Due: 08/01/40

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02299999 Org: User:
Start: 04/07/14 End: 12/31/25 Due: 12/31/26

Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00424203 Org: User:
Start: 01/31/06 End: 11/30/11 Due: 11/30/12

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05552001 Org: User:
Start: 10/05/23 End: 05/06/28 Due: 05/06/29

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

Phase: N/A Priority: Normal
NCT ID: NCT03412058 Org: User:
Start: 06/27/18 End: 12/31/25 Due: 12/31/26

Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00513058 Org: User:
Start: 06/30/07 End: 04/30/12 Due: 04/30/13

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT03870919 Org: User:
Start: 10/23/19 End: 10/23/27 Due: 10/23/28

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00056095 Org: User:
Start: 11/04/02 End: 08/17/16 Due: 08/17/17

Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

Phase: N/A Priority: Normal
NCT ID: NCT02339532 Org: User:
Start: 01/31/15 End: 07/08/24 Due: 07/08/25

Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05041842 Org: User:
Start: 12/17/21 End: 04/30/26 Due: 04/30/27

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Phase: N/A Priority: Normal
NCT ID: NCT01442246 Org: User:
Start: 07/31/11 End: 09/30/27 Due: 09/30/28

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Phase: N/A Priority: Normal
NCT ID: NCT03079011 Org: User:
Start: 03/22/17 End: 06/30/25 Due: 06/30/26

Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00003682 Org: User:
Start: 10/31/98 End: 03/31/01 Due: 03/31/02

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients with Leptomeningeal Disease

Phase: N/A Priority: Normal
NCT ID: NCT05800275 Org: User:
Start: 12/18/23 End: 06/30/27 Due: 06/30/28